Cori L. Daines
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cori L. Daines has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Bonnie Ramsey
Seattle Children’s Hospital, Seattle, Washington; and
2 shared publicationsBradley S. Quon
University of British Columbia and St. Paul’s Hospital, Vancouver, British Columbia, Canada
2 shared publicationsElizabeth Tullis
St. Michael’s Hospital, Toronto, Ontario, Canada
2 shared publicationsHiran Selvadurai
The Children’s Hospital at Westmead, Westmead, New South Wales, Australia
2 shared publications- Marcus Alexander Mall
Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
2 shared publications - Matthias Griese
Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, German Center for Lung Research (DZL), Germany
2 shared publications
Latest Publications
- Top Cited Papers
- 1 October 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (10) , 1901-1914
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study
Rationale: Clinical and real-world studies show that elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is efficacious and safe in people with cystic fibrosis (CF) ≥12 years of age with at least one F508del allele. Objectives: Given the potential for lifelong ELX/TEZ/IVA use, the long-term safety and efficacy of ELX/TEZ/IVA was assessed. Methods: In this phase 3, open-label, single-arm extension study, participants with F508del-minimal function genotypes (from 24-wk parent study 445-102 [n = 399]) or with the F508del-F508del genotype (from 4-wk parent study 445-103 [n = 107]) received ELX/TEZ/IVA (ELX 200 mg once daily, TEZ 100 mg once daily, and IVA 150 mg every 12 h) over 192 weeks. Measurements and Main Results: The primary endpoint was safety and tolerability. Mean exposure to ELX/TEZ/IVA was 172.6 weeks. Most participants had adverse events classified as mild (12.8%) or moderate (60.7%) in severity. Eighteen participants (3.6%) had adverse events that led to treatment discontinuation. After starting ELX/TEZ/IVA, participants had consistent increases in percent predicted FEV1 (ppFEV1), Cystic Fibrosis Questionnaire–Revised respiratory domain score, and body mass index, with decreases in sweat chloride concentration and pulmonary exacerbation rates; these improvements were maintained through 192 weeks. The mean annualized rate of change in ppFEV1 was 0.02 percentage points (95% confidence interval, −0.14 to 0.19) after initiation of ELX/TEZ/IVA. Conclusions: During this 192-week open-label extension study, the longest clinical study of a CFTR (cystic fibrosis transmembrane conductance regulator) modulator to date, ELX/TEZ/IVA remained generally safe and well tolerated. Participants had sustained improvements in lung function, respiratory symptoms, CFTR function, pulmonary exacerbation rates, and nutritional status. The estimated annualized rate of change in ppFEV1 suggests no evidence of pulmonary function loss across the study population over the 4-year treatment period. These results confirm the favorable long-term safety profile and durable disease-modifying clinical benefits of ELX/TEZ/IVA in adolescents and adults with CF. Clinical trial registered with www.clinicaltrials.gov (NCT03525574).
- 1 October 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (10) , 1901-1914
Top Cited PapersLong-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study
Rationale: Clinical and real-world studies show that elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is efficacious and safe in people with cystic fibrosis (CF) ≥12 years of age with at least one F508del allele. Objectives: Given the potential for lifelong ELX/TEZ/IVA use, the long-term safety and efficacy of ELX/TEZ/IVA was assessed. Methods: In this phase 3, open-label, single-arm extension study, participants with F508del-minimal function genotypes (from 24-wk parent study 445-102 [n = 399]) or with the F508del-F508del genotype (from 4-wk parent study 445-103 [n = 107]) received ELX/TEZ/IVA (ELX 200 mg once daily, TEZ 100 mg once daily, and IVA 150 mg every 12 h) over 192 weeks. Measurements and Main Results: The primary endpoint was safety and tolerability. Mean exposure to ELX/TEZ/IVA was 172.6 weeks. Most participants had adverse events classified as mild (12.8%) or moderate (60.7%) in severity. Eighteen participants (3.6%) had adverse events that led to treatment discontinuation. After starting ELX/TEZ/IVA, participants had consistent increases in percent predicted FEV1 (ppFEV1), Cystic Fibrosis Questionnaire–Revised respiratory domain score, and body mass index, with decreases in sweat chloride concentration and pulmonary exacerbation rates; these improvements were maintained through 192 weeks. The mean annualized rate of change in ppFEV1 was 0.02 percentage points (95% confidence interval, −0.14 to 0.19) after initiation of ELX/TEZ/IVA. Conclusions: During this 192-week open-label extension study, the longest clinical study of a CFTR (cystic fibrosis transmembrane conductance regulator) modulator to date, ELX/TEZ/IVA remained generally safe and well tolerated. Participants had sustained improvements in lung function, respiratory symptoms, CFTR function, pulmonary exacerbation rates, and nutritional status. The estimated annualized rate of change in ppFEV1 suggests no evidence of pulmonary function loss across the study population over the 4-year treatment period. These results confirm the favorable long-term safety profile and durable disease-modifying clinical benefits of ELX/TEZ/IVA in adolescents and adults with CF. Clinical trial registered with www.clinicaltrials.gov (NCT03525574).
- Top Cited PapersOpen Access
- 9 November 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (6) , 2202029
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least oneF508delallele: 144-week interim results from a 192-week open-label extension study
Background: In two pivotal phase 3 trials, up to 24 weeks of treatment with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious and safe in patients with cystic fibrosis (CF) ≥12 years of age who have at least oneF508delallele. The aim of this study is to assess long-term safety and efficacy of ELX/TEZ/IVA in these patients.Methods: In this phase 3, open-label, single-arm extension study, participants withF508del–minimal function (from a 24-week parent study; n=399) orF508del–F508del(from a 4-week parent study; n=107) genotypes receive ELX/TEZ/IVA at the same dose (ELX 200 mg once daily, TEZ 100 mg once daily and IVA 150 mg every 12 h). The primary end-point is safety and tolerability. A prespecified interim analysis was conducted when the last participant reached the Week 144 visit.Results: At the Week 144 interim analysis, mean duration of exposure to ELX/TEZ/IVA in the extension study was 151.1 weeks. Exposure-adjusted rates of adverse events (AEs) (586.6 events per 100 participant-years) and serious AEs (22.4 events per 100 participant-years) were lower than in the ELX/TEZ/IVA treatment group in the 24-week parent study (1096.0 and 36.9 events per 100 participant-years, respectively); most participants had AEs classified as mild (16.4% of participants) or moderate (60.3% of participants) in severity. 14 participants (2.8%) had AEs that led to treatment discontinuation. Following initiation of ELX/TEZ/IVA, participants had increases in forced expiratory volume in 1 s (FEV1) percentage predicted, Cystic Fibrosis Questionnaire-Revised respiratory domain score and body mass index, and had decreases in sweat chloride concentration and pulmonary exacerbation rates that were maintained over the interim analysis period. The mean annualised rate of change in FEV1% pred was +0.07 (95% CI −0.12–0.26) percentage points among the participants.Conclusions: ELX/TEZ/IVA was generally safe and well tolerated, with a safety profile consistent with the 24-week parent study. Participants had sustained improvements in lung function, respiratory symptoms, CF transmembrane conductance regulator function, pulmonary exacerbation rates and nutritional status. These results support the favourable safety profile and durable, disease-modifying clinical benefits of ELX/TEZ/IVA.
- 9 November 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (6) , 2202029
Top Cited PapersOpen AccessLong-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least oneF508delallele: 144-week interim results from a 192-week open-label extension study
Background: In two pivotal phase 3 trials, up to 24 weeks of treatment with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious and safe in patients with cystic fibrosis (CF) ≥12 years of age who have at least oneF508delallele. The aim of this study is to assess long-term safety and efficacy of ELX/TEZ/IVA in these patients.Methods: In this phase 3, open-label, single-arm extension study, participants withF508del–minimal function (from a 24-week parent study; n=399) orF508del–F508del(from a 4-week parent study; n=107) genotypes receive ELX/TEZ/IVA at the same dose (ELX 200 mg once daily, TEZ 100 mg once daily and IVA 150 mg every 12 h). The primary end-point is safety and tolerability. A prespecified interim analysis was conducted when the last participant reached the Week 144 visit.Results: At the Week 144 interim analysis, mean duration of exposure to ELX/TEZ/IVA in the extension study was 151.1 weeks. Exposure-adjusted rates of adverse events (AEs) (586.6 events per 100 participant-years) and serious AEs (22.4 events per 100 participant-years) were lower than in the ELX/TEZ/IVA treatment group in the 24-week parent study (1096.0 and 36.9 events per 100 participant-years, respectively); most participants had AEs classified as mild (16.4% of participants) or moderate (60.3% of participants) in severity. 14 participants (2.8%) had AEs that led to treatment discontinuation. Following initiation of ELX/TEZ/IVA, participants had increases in forced expiratory volume in 1 s (FEV1) percentage predicted, Cystic Fibrosis Questionnaire-Revised respiratory domain score and body mass index, and had decreases in sweat chloride concentration and pulmonary exacerbation rates that were maintained over the interim analysis period. The mean annualised rate of change in FEV1% pred was +0.07 (95% CI −0.12–0.26) percentage points among the participants.Conclusions: ELX/TEZ/IVA was generally safe and well tolerated, with a safety profile consistent with the 24-week parent study. Participants had sustained improvements in lung function, respiratory symptoms, CF transmembrane conductance regulator function, pulmonary exacerbation rates and nutritional status. These results support the favourable safety profile and durable, disease-modifying clinical benefits of ELX/TEZ/IVA.
- Open Access
- 14 September 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (1) , 119-123
Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor
- 14 September 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (1) , 119-123
Open AccessNon-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor